<section class="mx-auto flex w-full flex-col justify-between bg-white dark:bg-black-95 pt-0 p-0 mb-8 md:mb-18 print:block" data-test-id="card-container"><div class="flex flex-col flex-wrap print:block"><div class="w-full max-w-full"><div class="kW_p1 s_am s_aG s_a3 s_ak"><div class="kW_Iz s_dU"><a data-test-id="logo" title="Home" class="ak_e2 t_ei t_ez" href="/?source=content_type%3Areact%7Csource%3Asite_navigation"><span class="ak_hM t_ei t_ew"><svg class="ak_gz ak_fP ak_hI"><use xlink:href="#logo"></use></svg></span></a></div><header class="rV_Fv t_ei t_el t_es t_ez"><div class="vy_g t_ei t_el t_es s_dS ct_n1" data-test-id="quick-links"><div class="vy_We t_ei t_ek t_eu t_eC s_ct s_bO"><div class="vy_UN s_aC s_ah s_aW"><div class="yk_iV" data-test-id="themes-list"><ul class="yk_mT t_ei"><li class="yk_mU t_ei t_ek s_dI"><a data-test-id="theme-links-item" class="J_0 t_ej t_ek t_ep J_f9 J_fw aW_jl aW_jA aW_jR N_L" href="/earnings/earnings-call-transcripts?source=content_type%3Areact%7Csection%3Amain_content%7Csection_asset%3Athemes%7Cbutton%3Atranscripts%7Cfirst_level_url%3Aarticle"><span class=""><span class="yk_YG iR_vb">Transcripts</span></span></a></li></ul></div></div></div><div class="vy_Wd t_ei t_ek t_es"></div></div><div class="nf_il t_ei t_es"><h1 class="nf_Y s_dS aW_jt aW_jL aW_jR aW_kE aW_kW aW_k1" data-test-id="post-title">Acutus Medical, Inc. (AFIB) CEO Vince Burgess on Q1 2021 Results - Earnings Call Transcript</h1></div><div class="mb-18 flex justify-between text-medium-2-r md:mb-16 rV_RN t_ei t_ek" data-test-id="post-page-meta"><div><span class="nf_K7 nf_gW r_5" data-test-id="post-date">May 12, 2021 9:03 PM ET</span><span class="nf_gW r_5" data-test-id="post-primary-tickers"><a class="vC_Wk" href="/symbol/AFIB?source=content_type%3Areact%7Csection%3Amain_content%7Csection_asset%3Ameta%7Cfirst_level_url%3Aarticle%7Csymbol%3AAFIB">Acutus Medical, Inc. (AFIB)</a></span></div></div></header><div class="tt_N9 t_ei t_el t_es s_dS" data-test-id="author-brief"><div class="tt_ei t_ei"><a class="tt_Lj sm_Lj" href="/author/sa-transcripts?source=content_type%3Areact%7Curl_first_level%3Aarticle%7Csection%3Aauthor_brief%3Asa-transcripts%7Csection_asset%3Aauthor_brief%7Cauthor_icon"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="SA Transcripts profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static3.seekingalpha.com/images/users_profile/000/101/639/small_pic.png" srcset="https://static3.seekingalpha.com/images/users_profile/000/101/639/big_pic.png 2x, https://static3.seekingalpha.com/images/users_profile/000/101/639/big_pic.png 3x" width="36"></div></a><div class="tt_Oa t_ei t_ep t_ez s_cs"><a class="tt_Lj sm_Lj tt_Ji aW_jn aW_jB aW_jR s_dE sm_Ji" data-test-id="author-name" href="/author/sa-transcripts?source=content_type%3Areact%7Curl_first_level%3Aarticle%7Csection%3Aauthor_brief%3Asa-transcripts%7Csection_asset%3Aauthor_brief%7Cauthor_name">SA Transcripts</a><div class="tt_ri t_ei t_eu"><div class="rF_Ru aW_jl aW_jA aW_jQ tt_N8 r_5 aW_jl aW_jA aW_jQ">141.09K<!-- --> <!-- -->Follower<!-- -->s</div></div></div></div><div class="ll_IU" role="none"><button data-state-text="Following" class="J_0 t_ej t_ek t_ep J_fP J_fz aW_jm aW_jC aW_jR js_FS s_af s_bj s_aG s_a3 pL_F7 t_eE tt_wr s_cf aP_i9" data-test-id="follow-button" type="button"><span class=""><span class="js_FU t_ei t_ep" data-state-placeholder="Following"><span class="js_FV">Follow</span></span></span></button></div></div><div class="wD_XP s_dM"><button class="J_0 t_ej t_ek t_ep J_fP J_fz aW_jm aW_jC aW_jR yx_0 t_ej t_ek" data-test-id="play-button" type="button"><span class=""><svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg" class="yx_CB" data-test-id="play-button-play-svg"><path d="M0 16V0l16 8-16 8z" fill="currentColor"></path></svg><span class="yx_pl">Play Earnings Call</span></span></button></div><div><div class="paywall-full-content ja_f t_ei" data-test-id="article-content"><div class="ja_mg t_eC"><div class="ja_iS ja_E1" data-test-id="content-container"><p>Acutus Medical, Inc. (<span class="ticker-hover-wrapper">NASDAQ:<a href="https://seekingalpha.com/symbol/AFIB?hasComeFromMpArticle=false&amp;source=content_type%253Areact%257Csection%253Amain_content%257Cbutton%253Abody_link" title="Acutus Medical, Inc.">AFIB</a></span>) Q1 2021 Earnings Conference Call May 12, 2021 4:30 PM ET</p> <p><strong>Company Participants</strong></p> <p>Caroline Corner - Investor Relations</p> <p>Vince Burgess - President and Chief Executive Officer</p> <p>David Roman - Chief Financial Officer</p> <p><strong>Conference Call Participants</strong></p> <p>Robbie Marcus - JPMorgan</p> <p>Margaret Kaczor - William Blair</p> <p>Bill Plovanic - Canaccord</p> <p>Marie Thibault - BTIG</p> <p><strong>Operator</strong></p> <p>Good day, and thank you for standing by. Welcome to the Acutus First Quarter 2021 Earnings Call. At this time all participant lines are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator Instructions]</p> <p>I would now like to hand the conference over to Caroline Corner, Investor Relations. Please go ahead.</p> <p><strong>Caroline Corner</strong></p> <p>Thank you, operator. Welcome to Acutus' first quarter 2021 earnings call. Joining me on today's call are Vince Burgess, President and Chief Executive Officer; and David Roman, Chief Financial Officer.</p> <p>This call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements made on this call that do not relate to matters of historical fact should be considered forward-looking statements. Factors that may cause results to differ from these forward-looking statements are discussed under the forward-looking statements section in the press release attached to an exhibit to Acutus' Form 8-K filed with the SEC today, and are also discussed in more detail under the Risk Factors section in Acutus' most recent filings with the SEC, including the risk factors described in Acutus' Form 10-K.</p> <p class="iS_EF">Any forward-looking statements provided during this call, including projections for future performance are based on management's expectations as of today. Acutus' undertakes no obligation to update these statements except as required by applicable law. Acutus' press release for the first quarter of 2021 results is also available on the Acutus' website, www.acutusmedical.com under the Investors section and includes additional<span class="paywall-full-content invisible"> details about Acutus' financial results.</span></p> <p class="paywall-full-content invisible">The Acutus' website also has Acutus' SEC filings, which you are encouraged to review. A recording of today's call will be available on the Acutus' website by 5 PM Pacific Time.</p> <p class="paywall-full-content invisible">Now, I would like to turn the call<span class="paywall-full-content no-summary-bullets invisible"> over to, Vince, for his comments and first quarter 2021 business highlights.</span></p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Vince Burgess</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you, Caroline, and good afternoon to everyone joining us today. During today's call, I will provide an update on our key strategic priorities that I outlined in March. I will also comment on our first quarter results, which highlight improved performance in our business and commercial execution, and its ongoing turbulence in our end markets. David will follow-up with details on our financial and operational results, as well as our outlook for the second quarter and full year.</p> <p class="paywall-full-content invisible no-summary-bullets">Our team remains steadfast in our mission to transform patient care and physician experience. There is nothing more important to us than improving clinical outcomes and changing the treatment paradigm for the patients and customers that we serve.</p> <p class="paywall-full-content invisible no-summary-bullets">As discussed during our last call, technology and innovation leadership is top among our three areas to achieve our vision and drive the shareholder value. Veterans of the med tech space recognize that disruption is not linear and innovation is extraordinarily difficult, and that companies who consistently deliver here, ultimately rise to the top of their segments.</p> <p class="paywall-full-content invisible no-summary-bullets">Over the last quarter and in recent months, we continue to excel in this regard. With recent approvals, product advances, anecdotal case outcomes, as well as registry, investigator-sponsored and company-sponsored prospective clinical trial data that we are seeing, I am confident that we now have the most innovative suite of products, in each of the three key areas of electrophysiology: access, diagnosis, and therapy.</p> <p class="paywall-full-content invisible no-summary-bullets">Before going deeper here, I would like to take a moment to share a recent case from Europe that highlights the Acutus' mission and our core value proposition. This case involves a 76-year old male suffering from complex atrial tachycardia and heart failure. Due to significant comorbidities including liver dysfunction, the patient was not eligible for anti-arrhythmic drug treatment, so cardiac ablation was viewed as the best option for this individual.</p> <p class="paywall-full-content invisible no-summary-bullets">In the procedure, the physician took a stepwise approach to treat the arrhythmia, which included utilizing our mapping catheters, ultrasound transducers, and electrodes to quickly and efficiently create an anatomical map to the patient's right atrium, create a precise electrical wave propagation map of the whole right atrial chamber to quickly identify the area where the aberrant electrical activations first occurred, and deliver RF energy to restore the patient's normal heart rhythm, after using the AcQMap system to identify a crystal clear ablation target.</p> <p class="paywall-full-content invisible no-summary-bullets">Following the ablation, despite several attempts to induce the patient back into tachycardia through rapid pacing, the patient was non-inducible, confirming successful treatment.</p> <p class="paywall-full-content invisible no-summary-bullets">These steps, resulting in complete termination of atrial tachycardia took about five minutes, bringing the total procedure time to 90-minutes. By contrast, physicians report that using traditional systems with contact mapping, and such complex atrial tachycardia ablation procedures can take three to five hours, if not longer.</p> <p class="paywall-full-content invisible no-summary-bullets">Moving now to our operational progress. During our last earnings call, I set forth three strategic priorities that will drive our business and guide our focus. These include, technology and innovation leadership, commercial execution, and operational excellence. I'd like to provide an update on each of these pillars.</p> <p class="paywall-full-content invisible no-summary-bullets">I'll start with technology and innovation leadership. And for simplicity, step through our update in order of procedural flow, which is not necessarily weighted by revenue potential.</p> <p class="paywall-full-content invisible no-summary-bullets">At the start of any catheter procedure is access, and we are building a comprehensive and differentiated portfolio here. As previously announced, we received 510(<a href="https://seekingalpha.com/symbol/K?hasComeFromMpArticle=false&amp;source=content_type%253Areact%257Csection%253Amain_content%257Cbutton%253Abody_link" title="Kellanova">K</a>) clearance for our AcQCross solo family of universal transseptal crossing devices. This is the first and only transseptal puncture system, specifically engineered to pair and mate seamlessly with Acutus own suite of sheets, and with sheets sold by other manufacturers.</p> <p class="paywall-full-content invisible no-summary-bullets">In the United States, there are over 300,000 electrophysiology and structural heart procedures per year, involving the use of transseptal crossing devices. We began U.S. commercial launch of the new family of transseptal products in late April. And the early interest reinforces the value of the technology, and what it brings to physician users.</p> <p class="paywall-full-content invisible no-summary-bullets">As further announced today, we've received CE Mark approval for our complete line of transseptal crossing device products, in addition to an expanded array of other sheets and access products. These approvals help complete our offering in CE Mark countries to cover the entire procedural continuum. We expect to launch these products during the second quarter.</p> <p class="paywall-full-content invisible no-summary-bullets">Overall, our portfolio of transseptal and other access devices provides a natural entry point into any account in the U.S. or CE Mark countries, and complements our core mapping and guided ablation portfolio.</p> <p class="paywall-full-content invisible no-summary-bullets">Next in the procedure is diagnosis and therapy guidance. This is the area where Acutus is most significantly differentiated versus our competition, with our AcQMap mapping system. We have had good success educating our broader physician user base, on the results from the core to boundary paper published out of Oxford and the Royal Brompton Hospital in February of this year. This ablation strategy and technique, which is uniquely enabled by our AcQMap technology demonstrated strong clinical outcomes in challenging to treat persistent AF patients in real world settings. Specifically, 87.5% of patients in this independent study were free from AF in the absence of anti-arrhythmic drugs at 24-months.</p> <p class="paywall-full-content invisible no-summary-bullets">Also, we have now completed enrollment and 12-month follow-up of our RECOVER study, and look forward to sharing those results soon, once the final data are analyzed. To remind you, RECOVER is a prospective multicenter study conducted in the EU and Canada, that uses the AcQMap system in patients, who have failed an initial or as many as two prior ablation procedures. We hope that these data will reinforce the results from both our own landmark UNCOVER AF study, and the independent core to boundary study.</p> <p class="paywall-full-content invisible no-summary-bullets">Finally, we move to therapy. As you may recall, we launched our AcQBlate Force-Sensing Ablation Catheter and System in the UK and Europe earlier this year. This product line is approved for use in all chambers of the heart and CE governed markets, and was very well-received during our limited market release. We are now in full market release. And so far, sites are reporting that the AcQBlate ablation system performs extremely well, when paired with our AcQMap therapy guidance system.</p> <p class="paywall-full-content invisible no-summary-bullets">In early April, we initiated our U.S. IDE trial for AcQBlate Force-Sensing Ablation Catheter and System for the treatment of right atrial flutter. As a reminder, right atrial flutter ablation procedures account for approximately 30% of U.S. cardiac ablations, and are projected to reach 200,000 procedures annually by 2025, based on third-party industry research. The trial is up and running at sites in the U.S. and Europe, and we continue to project completing enrollment by the end of this year, with approval toward the end of 2022.</p> <p class="paywall-full-content invisible no-summary-bullets">With our expanding product portfolio, we are positioned to become the partner of choice for electrophysiologist in the management and treatment of complex patients, such as redo ablations, treatment of complex tachycardia, and a typical flutter, and, of course, atrial fibrillation. To that end, our atrial fibrillation U.S. IDE application, where we plan to study the AcQBlate Catheter and System in paroxysmal and persistent AF patients is currently under review by the FDA. We are on track to commence this study in the second-half of this year, as previously communicated.</p> <p class="paywall-full-content invisible no-summary-bullets">Turning now to our second key priority, commercial execution. In Europe and the UK, our direct and Biotronik distribution teams continued to drive solid case volumes and capital sales and placements. These operating segments led our first quarter results, and we continue to see solid performance from these groups, despite an ongoing COVID headwinds in major European markets.</p> <p class="paywall-full-content invisible no-summary-bullets">As for the U.S., we are seeing improved momentum in this business. Our new Chief Commercial Officer, Duane Wilder, who joined us in March is providing great leadership direction and a disciplined go to market strategy. We are executing on our plan for more rigorous account segmentation, ensuring the right physician training and engagement and driving growth and utilization.</p> <p class="paywall-full-content invisible no-summary-bullets">Lastly, we continue to grow and scale the business, as well as launch an impressive array of new products. Operational excellence will become increasingly important as a driver for the company. We are better aligning our production volumes and inventory within market demand, as well as driving improved yields for key product lines. David will discuss these dynamics in more detail later in the call. But I want to underscore the importance of our operations and manufacturing efforts to the long-term strength of the business.</p> <p class="paywall-full-content invisible no-summary-bullets">As for our results during the first quarter, we generated sales of $3.6 million compared to $1.6 million in Q1 of 2020, and compared to $2.6 million in Q4 of 2020. Both the year-over-year sequential sales growth was driven by higher procedure volumes globally, and increased capital equipment sales.</p> <p class="paywall-full-content invisible no-summary-bullets">We increased the worldwide installed base of second generation AcQMap consoles to 57 at the end of Q1, up from 51 at the end of Q4, bringing the total installed base of AcQMap consoles to 62, as of March 31, 2021, versus 58 at the end of last quarter. We exited the quarter with a good backlog and have seen placements pick up with four net new installations, already completed as of April 30, equaling our net additions in all of Q1.</p> <p class="paywall-full-content invisible no-summary-bullets">Importantly, many of the new system placement so far in 2021 are at major academic and high volume community institutions, consistent with our strategy to be more targeted with capital placements.</p> <p class="paywall-full-content invisible no-summary-bullets">Turning to procedure volumes and utilization, we continue to see a wide standard deviation across accounts and geographies. In the United States, we saw progressive improvement in utilization per system per month, with March utilization rates about 50% above those we saw in January, with the COVID impact on procedure volumes moderating. We do see some lingering COVID impact as it relates lab access for medical device vendors, thus limiting some of our ability to train both physicians as well as our own mappers.</p> <p class="paywall-full-content invisible no-summary-bullets">In addition to some limitations on access, the capital equipment environment remains somewhat constrained, and contract processes are still longer than we'd expect in a normal operating environment.</p> <p class="paywall-full-content invisible no-summary-bullets">All that said, we continue to believe that more of the burden is on us to execute in the U.S., versus the impact of the external environment. Recent trends are encouraging, the team is showing stronger execution, and we are optimistic that this will continue.</p> <p class="paywall-full-content invisible no-summary-bullets">In the UK and Europe, the dynamic is quite different, as COVID remains a significant issue for much of the region. During the first quarter, only half of our consoles were consistently active due to hospital and government restrictions on elective procedures.</p> <p class="paywall-full-content invisible no-summary-bullets">Importantly, within active centers, procedure volumes and console utilization has doubled versus the prior year, reflecting solid commercial execution, as well as the benefits of having our mapping and ablation product lines on the market over there.</p> <p class="paywall-full-content invisible no-summary-bullets">In the UK, which is our largest market currently in Europe, we are seeing some stabilization as COVID vaccination rates and economic recovery are more closely following that of the U.S. Elsewhere in Europe, we still see rolling COVID shutdowns and slowdowns, and our team is working hard to maximize the performance on active consoles.</p> <p class="paywall-full-content invisible no-summary-bullets">As mentioned previously, laid in the first quarter, we also transitioned our AcQBlate Force-Sensing Ablation Catheter and System into full commercial launch. Feedback from the clinical community remains strong, which was further highlighted by case presentations at the European Heart Rhythm Association virtual conference in April. We expect AcQBlate utilization to ramp meaningfully throughout the year, and for this product line to be a key driver of future performance.</p> <p class="paywall-full-content invisible no-summary-bullets">Lastly, our partnership with Biotronik continues to deliver strong results, while installations were delayed due to COVID and there is concentration in markets like Germany, where elective procedures have largely been on hold, we are starting to see improvements. The Biotronik commercial team remains heavily engaged on training and implementation, and we expect this collaboration to be a critical driver over the short, medium, and long-term.</p> <p class="paywall-full-content invisible no-summary-bullets">Overall, I'm extremely proud of the progress our teams are making to execute our strategy and bring innovative solutions to physicians, patients and healthcare systems around the world. First quarter results exceeded our internal expectations, and we are continuously sharpening our focus to drive enhanced performance.</p> <p class="paywall-full-content invisible no-summary-bullets">Through the rest of 2021, we expect to have several clinical data, regulatory and product milestones that will further illustrate our long-term value proposition. We look forward to providing these updates throughout the year.</p> <p class="paywall-full-content invisible no-summary-bullets">With that, I'll now turn it over to David for our financial results. David?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>David Roman</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you, Vince, and good afternoon, everyone. During my remarks today, I will provide details on first quarter 2021 operating results, as well as your outlook for the second quarter and full year.</p> <p class="paywall-full-content invisible no-summary-bullets">In today's press release and 8-K filing, you will notice updated disclosures on our P&amp;L. These changes include a full non-GAAP P&amp;L, whereas previously, we only provided adjustments at the net income and loss line. In today's call, I will be referring to non-GAAP financial measures for all P&amp;L line items. A full reconciliation of GAAP to non-GAAP financial measures is presented in our press release for your reference.</p> <p class="paywall-full-content invisible no-summary-bullets">Revenues for the first quarter of 2020 were $3.6 million, up from $1.6 million in Q1 of 2020. The Q1 year-over-year revenue increase was driven by procedural adoption for our broad range of EP products and transseptal access devices, direct capital sales of our AcQMap console and the implementation of the Biotronik distribution agreement.</p> <p class="paywall-full-content invisible no-summary-bullets">Sales in our direct businesses of $2.4 million increased nearly 60% from $1.5 million in the first quarter of 2020. Disposal, utilization and service contract revenue advanced 77% versus the prior year, and accounted for the majority of Q1 sales growth. Revenue through distribution agreements of approximately $1.2 million compared to $36,000 in the prior year's first quarter, driven by both procedure volume growth and capital sales.</p> <p class="paywall-full-content invisible no-summary-bullets">Non-GAAP gross margin was negative 89% for the first quarter of 2021, compared with negative 95% in the first quarter of 2020. As referenced in our press release, there were several discrete items that were significant gross margin headwinds in the first quarter.</p> <p class="paywall-full-content invisible no-summary-bullets">A meaningful impactor impacting gross margins with the write-off of excess and obsolete inventory, resulting from that transition to a new product line and fully in-house manufacturing for our transseptal access product lines. We also took additional excess and obsolete reserves for short shelf life products.</p> <p class="paywall-full-content invisible no-summary-bullets">In aggregate, excess and obsolete inventory charges impacted non-GAAP gross margin by approximately $800,000, or 23 points to the gross margin line. Excluding these charges, non-GAAP gross margin was approximately negative 66%. We have not excluded E&amp;O charges from non-GAAP results, but wanted to highlight this number given its magnitude and our view that this is a one-time adjustment.</p> <p class="paywall-full-content invisible no-summary-bullets">As you may remember, on our last call, I discussed the importance of demand planning to support commercial and manufacturing operations. We're making excellent progress in this regard, as well as executing several costs and yield improvement initiatives.</p> <p class="paywall-full-content invisible no-summary-bullets">In addition, several of our new product launches, such as our next generation AcQMap mapping catheter that is now available on both the U.S. and CE Mark countries, carry a better COGS position. The combination of better yields, forecasts alignment and new product update should all help drive improved gross margins starting in Q2.</p> <p class="paywall-full-content invisible no-summary-bullets">Non-GAAP R&amp;D expenses were approximately $9 million in the first quarter compared with $7.8 million for the same period of 2020. The increase in R&amp;D expenses was primarily related to investments in the AcQBlate Force-Sensing Ablation Catheter, our pulsed field ablation program, transseptal access products, software development and upgrades to our AcQMap mapping catheter.</p> <p class="paywall-full-content invisible no-summary-bullets">Non-GAAP SG&amp;A expenses were $13.8 million in the first quarter of 2021, compared with $8.7 million for the same period last year. The increase was primarily due to the expansion of our commercial team in conjunction with our full global launch, and an increase in G&amp;A for public company-related costs.</p> <p class="paywall-full-content invisible no-summary-bullets">Excluding specified items, our non-GAAP net loss for the first quarter of 2021 was $27.3 million or $0.97 per share, compared to a non-GAAP net loss of $19 million or $1.11 per share, after giving effect to the pro forma conversion of our convertible preferred stock. Our total cash balance at the end of first quarter of 2021 was $106.9 million.</p> <p class="paywall-full-content invisible no-summary-bullets">Looking to the remainder of 2021, I would like to provide some further detail regarding our full year and second quarter outlooks, that were included in today's press release. Our first quarter results showed better performance from where we exited 2020. In the U.S., COVID-related headwinds are fading and we are starting to see strong procedure volume at major accounts. At the same time, we continue to see shutdowns across key markets in Europe, that is making performance somewhat uneven.</p> <p class="paywall-full-content invisible no-summary-bullets">All that said, we are keenly focused on the variables that we can control, such as commercial execution, product launches, and manufacturing. As a result, we expect to see continued sequential improvement in the second quarter, and project sales to range between $3.8 million and $5 million.</p> <p class="paywall-full-content invisible no-summary-bullets">Based on current trends and planned internal initiatives, we continue to anticipate a more meaningful step up in Q3 and Q4. On our last earnings call, we outlined five key factors to support this growth throughout the year, I'd like to give you an update on each of these drivers.</p> <p class="paywall-full-content invisible no-summary-bullets">The first is the timing of capital sales and conversions. We have several evaluations that are reaching completion. Our teams are working to convert these into capital sales leases or capital utilization deals.</p> <p class="paywall-full-content invisible no-summary-bullets">Second is the pace of manufacturing ramp for AcQBlate and transseptal crossing devices. In response to higher demand, we are adding resources to support the AcQBlate commercial ramp in Europe. This should drive improve yields and facilitate higher production volumes, and correspondingly revenue. As for transseptal crossing devices, we've resolved all backorders as of the end of April, and are seeing manufacturing ramp accordingly.</p> <p class="paywall-full-content invisible no-summary-bullets">Third is new product launches. We expect to see increased contribution from new product launches over the course of the year, including AcQBlate, the AcQCross family of transseptal crossing devices, our next generation AcQMap mapping catheter, and the AcQGuide VUE sheaths.</p> <p class="paywall-full-content invisible no-summary-bullets">Fourth is end market conditions. As discussed earlier, we continue to see improvements in the U.S., while conditions in Europe remain variable by hospital, by market and by month. Regardless, our forecasts do assume that the global end markets that we serve show signs of improvement to the back-half of the year, and nothing we see today gives us pause on this assumption.</p> <p class="paywall-full-content invisible no-summary-bullets">Lastly, we continue to expect improved commercial execution in the U.S. to be a major driver. We are strengthening and expanding our team, investing in critical training resources and ensuring we have the right level of account coverage.</p> <p class="paywall-full-content invisible no-summary-bullets">With the first quarter now complete and taking into account our second quarter guidance, we reiterate our view that 2021 revenue will be heavily weighted to the back-half of the year, reflecting the aforementioned drivers and the well-documented headwinds we experienced entering the year. Putting this all together, we continue to project full year revenue to be in a range of $22 million to $30 million.</p> <p class="paywall-full-content invisible no-summary-bullets">I will now turn the call back to Vince for closing remarks.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Vince Burgess</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you, David. As I reflect on the cadence of our performance in the first quarter, and here early in the second quarter, the trajectory of our business is gaining momentum. Our commercial execution globally is strengthening, and I'm confident we have the right team in place.</p> <p class="paywall-full-content invisible no-summary-bullets">In addition, we continue to advance several key products through our pipeline, and expect 2021 and 2022 to be very active years for product approvals and registrations. Lastly, we are intensifying our efforts to improve operational performance. And these initiatives are starting to take hold.</p> <p class="paywall-full-content invisible no-summary-bullets">We appreciate your continued interest and support, and we will now open the call to your questions. Operator?</p> <p id="question-answer-session" class="paywall-full-content invisible no-summary-bullets"><strong>Question-and-Answer Session</strong></p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">[Operator Instructions] Your first question comes from the line of Robbie Marcus with JPMorgan. Your line is now open.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Robbie Marcus</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Oh, great. Thanks for taking the question. And good evening. David, welcome to your first earnings call.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">David Roman</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thanks, Robbie.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Robbie Marcus</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Just wanted to start, as we think about guidance for the rest of the year, 2Q probably came in just a hair lower, the way the Street was thinking placements in first quarter were a bit lower. It's still calling for pretty meaningful acceleration in third quarter and fourth quarter. So I'd say, A, what gives you confidence that sales can accelerate like that in third and fourth quarter? And what kind of environment is that assuming?</p> <p class="paywall-full-content invisible no-summary-bullets">And then B, how should we think about the balance of what you're assuming for new system placements, and then utilization at system placements to get to those revenue numbers?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Vince Burgess</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">So, in terms of the environment, that's all kind of predicated on. I think, we're kind of assuming as we get into the back-half of the year, in the U.S., we're looking at an environment that approaches normalcy. So, really the lingering thing we're seeing, primarily on the East Coast, and Northern Midwest is some continued friction in terms of access to labs. So we can bring one person in versus one person plus mapper trainee or something like that.</p> <p class="paywall-full-content invisible no-summary-bullets">But other than that, I think most of our accounts are kind of up and running pretty close to normal operations.</p> <p class="paywall-full-content invisible no-summary-bullets">Europe, we're assuming that Europe will be relatively light in August, as it normally is, from a procedural perspective, and then start to get back towards normalcy in September, October and November, which have been historically quite good for us over there. And then obviously, the seasonality in December with the holiday and whatnot, we expect some kind of a normalized kind of reduction there. So that mean, that's kind of my sense of just the overall environment.</p> <p class="paywall-full-content invisible no-summary-bullets">In terms of systems placements, I think the models have it pretty well, that I've seen most recently have a pretty well right, in terms of what we think we can do, in terms of placements. Q1, in the prior call, when we talked about how we're thinking about Q1, I tried to get across with the targeting that we were really focusing in on, and with adding Duane and really thinking about where we place our systems, the types of physicians we want to be working with at this phase of our evolution.</p> <p class="paywall-full-content invisible no-summary-bullets">I kind of had the sense that we would probably move a few consoles around, and it might be a little bit lighter than the rest of the year in terms of placements, and then as we came into Q2, things would start to ramp up again. And as I mentioned in my prepared comments, I think our net new adds in April alone in terms of installed base equal to Q1. So, I think we're on track now Q1 was just a little light, almost intentionally. We really wanted to make sure everything we installed was in the right place, the expectations were set properly. And we have the right Doc's identified.</p> <p class="paywall-full-content invisible no-summary-bullets">Did I miss any of Robbie's questions?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">David Roman</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">I think Robbie, the only thing that I would add, you commented on the second quarter a couple of variables impact that, which are obviously the pacing of capital sales. There is, as you know, each capital sales anywhere from $200,000 to $300,000 for us. So as those might move quarter-to-quarter, they can have an impact on our interim results.</p> <p class="paywall-full-content invisible no-summary-bullets">I would also point out, the COVID dynamic in Europe did have an impact on our business entering the quarter. But we have since started to see that moderate quite significantly and are encouraged by the trends we're seeing today in Europe. And the guidance for the balance of the year assumes that what we're seeing today continues.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Vince Burgess</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">We also with our Biotronik partner had forecasted a few additional placements in Q1, that were pushed out due to continuing COVID issues in Austria, Australia, and Malaysia.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Robbie Marcus</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Got it. And then David, how do we think about expenses ramping through the year? Obviously, there's going to be more meaningful revenue in third and fourth quarter. How do we think about the scale up of SG&amp;A and R&amp;D throughout the year? Thanks.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">David Roman</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Sure, Robbie. While we are expecting -- you're correct, revenues ramp throughout the rest of the year, we would actually not expect a meaningful expense ramp to follow that. Let me walk through some of the specific reasons here.</p> <p class="paywall-full-content invisible no-summary-bullets">Starting with R&amp;D, we have over the past couple of years really sprinted to pull together a wide and diverse portfolio of differentiated products. And a lot of that investment in call it the pure development or research phase is sunsetting. So as we think about our R&amp;D investment, the rest of the product portfolio that we've been able to create is largely reflected in trailing R&amp;D expense. And we would expect to be able to read to prioritize that more judiciously going forward.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Vince Burgess</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">And if I could just jump on that really quick before you move on. Robbie, you've been focused on the R&amp;D spend throughout our -- getting to know you, and you're getting to know us.</p> <p class="paywall-full-content invisible no-summary-bullets">The thing I want to point out here is over the last 18 to 24-months, we have revved basically our entire system. And when I say revved I mean, executed on upgrades of the console, the software as many as six times. And each individual disposable component that we manufacture and sell has been revved from Gen 1 one Gen 2, and as of today, which we announced, are basically nearly our final CE Mark approvals, of those are now in production, approved and available for launch in the U.S. and Europe, and through our distribution partner Biotronik.</p> <p class="paywall-full-content invisible no-summary-bullets">So, I have to tell you, it's been a -- all these rounds, all these changes are intended to address the early feedback we've received from our customers, about things that are great about the products, things that need additional tweaking, and improvement and some cost reduction things we've been working on.</p> <p class="paywall-full-content invisible no-summary-bullets">I would say the majority of that heavy lift is now behind us, and we feel great about the full array of second generation products, which we have cranked out of our R&amp;D organization.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">David Roman</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">On SG&amp;A Robbie, as I look at it, I look at it sales marketing, and in G&amp;A, we will continue to make investments in the sales force. And I see opportunities to manage tightly marketing expense, as well as drive down G&amp;A. We did have some, I would say, transitionary expenses in the first quarter related to senior level management turnover that will not recur going forward.</p> <p class="paywall-full-content invisible no-summary-bullets">And then, while you didn't ask about gross margins, we brought up operating expenses, but I do want to point that out that gross margin will also be a significant lever as we go forward, and we are starting to see that materialize in real time.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Vince Burgess</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">And when you say in real time, we're talking about in Q2 and in April, specifically correct.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Robbie Marcus</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">And when do we see that turned positive?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">David Roman</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">So for gross margin to be positive, we have to be at a run rate of about call it $9 million a quarter, with a mix of 80-20 disposables and capital, and that should occur exiting the third quarter with a full quarter of gross margin positivity in Q4. There are some opportunities we are working on right now, specifically around yield improvement that could pull that forward.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Vince Burgess</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">And to be clear, standard margins on our disposables are presently already positive. It's the overhead and obviously, we're getting ahead on.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Robbie Marcus</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Great. Thanks a lot.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Your next question comes from Margaret Kaczor with William Blair. Your line is now open.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Margaret Kaczor</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Hey, guys, thanks for taking the questions. Maybe first one for me, you guys brought Duane on board. You've talked about these commercialization changes. Can you give us good sense? It's a two-fold question.</p> <p class="paywall-full-content invisible no-summary-bullets">So one, can you give us a sense of utilization within accounts? The March rates were encouraging, but as we look at that, is that coming from accounts reopening backup post COVID, or share taking within them?</p> <p class="paywall-full-content invisible no-summary-bullets">And then as we think about utilization climbing from here, what's being assumed in some of those guidance assumptions and the ranges?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Vince Burgess</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">We're dealing with small numbers of hospitals and accounts, relatively speaking. In Europe, over half of our consoles basically have been down in all of Q1, 100% due to COVID. And couple of -- some of them are still down or doing very, like procedural volume, and some are actually still going up and down. In Rotterdam, the Netherlands, Belgium, we're still seeing some slowdowns, and then return to where -- we are seeing generally though, the center's getting back online.</p> <p class="paywall-full-content invisible no-summary-bullets">In the UK, they brought these state of the art hospitals that were really standing our EP labs over the last six or nine months down in a basically field hospitals to deal with COVID. And now they're bringing them back up in the state of the art EP labs again. And if you talk to our folks on the ground, it's taken a little bit longer than expected to get there. But they are getting there. And we expect the UK, probably to lead the charge in terms of coming back up to more normal utilization levels.</p> <p class="paywall-full-content invisible no-summary-bullets">We were on our update call with the entire European team for a couple hours this morning, getting an update. And this is just an outstanding team, highly mature, very experienced and tenured group with a great handle on the business. And we feel like they've properly positioned with the right customers this product, and the technology is generally being used in the more complex procedures. And, we see that we are becoming the technology, the product of choice in redos and more complicated persistent patients and complicated tachycardia. So that's how we drive utilization there.</p> <p class="paywall-full-content invisible no-summary-bullets">Now, I'd like to be at a place where we're at 25%-30% plus of complex procedures in accounts where we are installed. That's, I think, a great target for us.</p> <p class="paywall-full-content invisible no-summary-bullets">The U.S., I would say the U.S. is a bit more of a mixed bag. We have accounts that are rolling nicely and generating pretty consistent utilization. We have a number of accounts that had very low utilization. In the last quarter, we had a group of account or consoles that were in accounts that were part of a larger group, where we had some contracting issues that we had to get through, which we actually just got through last week, and we are excited to restart, particularly one of those accounts that did four cases yesterday with us in the single day, in a single room.</p> <p class="paywall-full-content invisible no-summary-bullets">So it's really kind of a mixed bag of those sorts of issues in the U.S. But for us, it's all about making sure that our mappers are well-trained. We have the right message. One of the things we're really leaning on heavily now is training our U.S. mappers to deliver over the core-to- boundary diagnostic and ablation strategy that came out of our European experience over the last couple of years, which was written up in kind of a cookbook step-by-step fashion and that quarter boundary paper out of Oxford. And having that recipe that playbook for our mappers, and our sales reps to deliver over to U.S.-based EPs, I think is going to serve us very well.</p> <p class="paywall-full-content invisible no-summary-bullets">So, those are some of the kind of the key drivers, and David, I donâ€™t know if anything you want to add based on?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">David Roman</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Margaret, I would add, as we think about overall all the utilization, our guidance does contemplate that utilization rates continue to improve from what we saw in the first quarter. And that is, if I look across the different parts of the world, we are comfortable in that assumption, because we saw pretty consistently January to February to March sequential progression in utilization, and especially to bring back online some critical high volume centers, that also contributes to the overall revenue performance.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Margaret Kaczor</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Okay. And part of what I'm trying to get is, what did April look like, how does that set up for Q2, it sounds like maybe there's some easier low-hanging fruit as some of these centers still come back. So, we should start to see that utilization rise just across the installed base, without assuming huge cheer taking until hopefully later in the back-half of the year. Am I hearing that right?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">David Roman</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">That's correct.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Vince Burgess</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">I think that's fair.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Margaret Kaczor</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Okay. And then, if we look at the new installs, the four that you gave in April seem pretty good. I couldn't quite tell based on what you told Robbie, how much of that maybe had moved from Q1 to Q2. How should we think about that as a good monthly rate going forward? What would you guys be happy to see?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">David Roman</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">I think that would be an okay starting point as a monthly rate.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Vince Burgess</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Globally, I mean, global. Yes, Europe and I think kind of that pace.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">David Roman</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">I would say, yeah, at least at that pace Margaret, it would be our expectation. And in terms of the shifting of timing, whether it's Q1 into Q2, we don't have a ton of control necessarily over when systems get placed, it is around contracting and hospital availability to do an install. The key thing that we want to make sure we communicate coming out of Q1 is, as we think about being highly targeted of their accounts, being targeted does not necessarily mean limiting the number of opportunities. We still see a significant opportunity to grow our installed base, as we come out of that account segmentation and targeting initiative in Q1, we start to execute on that with more vigor in Q2, that helps us with -- that contributes to the U.S. placements.</p> <p class="paywall-full-content invisible no-summary-bullets">And then, there clearly still is some COVID overhang outside the U.S. that is resolving and should continue to resolve as we move forward.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Margaret Kaczor</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Okay. Perfect. Thanks, guys.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Your next question comes from Bill Plovanic with Canaccord. Your lines now open.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Bill Plovanic</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Great. Thanks. Good evening. Thanks for taking my questions. So, just clarification of Margaret's question. The four installs in April, you said you'd be happy to see that. Is that four a month or four a quarter globally? Just for clarification.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Vince Burgess</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Yeah, that'd be a good monthly figure. I think we'll have months where we do more than that, we have a month or two, we do less. But that's I think is a good pace for us.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Bill Plovanic</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Okay. And then, just as we get out here, definitely last year is a challenging year given the macro environment, bringing new technology to market. I think you've covered that in your opening remarks. But, what is the first year of learnings or the launch learnings? How have you implemented that into the commercial strategy, both direct in the U.S., OUS and with your distributor partners?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Vince Burgess</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">In talking with our European team, we really spent a lot of time on that in the last couple months, making sure we're crystallizing that and trying to think about how it translates into the U.S. So Europe, we feel great about not only where we are, but where we're headed utilization wise, and where we're headed in terms of additional console installs and ablation. We call it equipped electronics stack installs.</p> <p class="paywall-full-content invisible no-summary-bullets">We've got a nice number of therapy electronic stacks already, and I think we expect to double that installed base of electronic stacks in this quarter alone. So, we're trying to bring that over now to the U.S.</p> <p class="paywall-full-content invisible no-summary-bullets">I think, for me, the number one -- two things, I guess. Number one, we need to do a better job of bringing over that European experience in our training of our commercial team here in the U.S., and we're really focused in on that.</p> <p class="paywall-full-content invisible no-summary-bullets">And number two, it's really about targeting. And when I say targeting, the place for us to go is centers where there are one or more physicians, who aren't satisfied with their current procedural technique for persistence, for redos, for tachycardias, and are ready, willing and able to think about modifying their workflow, modifying their technique to try and improve their acute and long-term success, versus just taking a cool new system that has a lot of whiz bang, or optics to it, but be unwilling to actually modify their technique. That's just not a great place for us right now. And frankly, it never will be.</p> <p class="paywall-full-content invisible no-summary-bullets">The only way you can deploy our system to make to do things differently, as if you're willing to go away from just a standard PVI ablation approach, or PVI plus posterior wall. If that's just what you're hell bent on doing, as an electrophysiologist, the competing systems do a very adequate job of an empiric anatomically-based ablation approach. We think in Core-to-Boundary and UNCOVER really point to that. We think that there's more that can be done. We can be more patient-focused, more adaptive, more individualized, for each individual patient. And, hope and expect to see better outcomes.</p> <p class="paywall-full-content invisible no-summary-bullets">And we think only our system really has the potential to facilitate that, because the current systems, it's just biologically implausible to use a conventional contact mapping system to map an individually ablate, a patient who's in a non-regular rhythm. So someone that has an irregular rhythm, not in sinus rhythm, it's just not really plausible to map those patients.</p> <p class="paywall-full-content invisible no-summary-bullets">We think with our system, we bring that to the party, and that can help take the physician and the procedure to the next level.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Bill Plovanic</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">That's actually really helpful. And then, Vince, how does that translate into the funnel of potential accounts, as you said, the targeting? Does that take the funnel of what you originally expected and cut it down by 10%, 50%, 90%? How should we think about that, in terms of kind of this initial ramp?</p> <p class="paywall-full-content invisible no-summary-bullets">And then as you think of the accounts that have come on board, I think you gave us some clarity on that the U.S. accounts are doing the more difficult cases, and it's really that's what they're using it for. Have you seen it kind of move into that paroxysmal case yet? And those are my questions. Thanks so much for taking them.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Vince Burgess</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">As you look at our initial models that we worked with our analysts to put together last spring, in the rollout of consoles and the pace of those consoles, and just the sheer number of consoles set against the total number of EP rooms in the U.S. and around the country. We mapped out a pretty modest share of rooms.</p> <p class="paywall-full-content invisible no-summary-bullets">When you go around the world and you talk to doctors about how they feel about the tools they have, and how confident they are and their success rates in treating persistent cases and redos and quickly treating tachycardia that are complex, the vast majority of the physicians we talked to feel like there's plenty of room to improve. Now, not all of them want to go through the sometimes arduous process of changing workflow to do that, and those folks probably aren't for now, for us. A lot of these physicians, however, give all signs of being ready, willing and able to roll up their sleeves and do that work, and work with us.</p> <p class="paywall-full-content invisible no-summary-bullets">And I would say there are plenty of EPs out there that feel that way, and certainly a sufficient number to hit that three and five year kind of rollout trajectory, that we spelled out a year ago. So I see no major change in how we think about the funnel, based on what we've learned and experienced.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Bill Plovanic</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Great. Thank you.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Your next question comes from Marie Thibault with BTIG. Your line is now open.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Marie Thibault</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Hi, good evening. Vince and David, thank you for taking the questions. I want to ask one here on AcQBlate and the full market release that you're headed into. In Europe, I know you mentioned you're adding some resources there. And given some of the COVID constraints, I would love to hear how you're thinking of the cadence of that rollout? Is that mostly kind of a second-half event as we think about our models?</p> <p class="paywall-full-content invisible no-summary-bullets">And what's the latest on feedback from AcQBlate users? What's it doing to their utilization? And sort of any qualitative anecdotes you can give there?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Vince Burgess</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Okay. Yeah, I've been in med tech for a long time. And usually, in emerging companies, emerging technologies, you go over there first and then you focus primarily on the U.S., because of reimbursement and other issues that make Europe hard to do well in. We're doing really well in Europe. And I think it's a great proof point for us in terms of the value proposition that we bring with our mapping system. And as we have now put our mapping system together with the AcQBlate, and I want to -- this is an important distinction here, this is not just a catheter, this is the AcQBlate catheter paired together with the force monitoring unit that we have, that is our unit, together with a concurrently designed RF generator and pump, that was designed by our partner Biotronik as one unit, basically, it works just seamlessly together. I think it is the best electronic stack in the therapy business presently in the market, anywhere in the world.</p> <p class="paywall-full-content invisible no-summary-bullets">And when you pair that up with a catheter, which I think can go toe to toe with any catheter, it's just a great, great unit. We are also finding that when we take our mapping system, and have it used along with an Abbott catheter, comp generator, force-sensing unit, these weren't designed to work flawlessly together from the get go. And it just imposes some workflow issues. You have a higher likelihood of having to do troubleshooting, and things like that you may not have as clean as signals consistently room to room to room.</p> <p class="paywall-full-content invisible no-summary-bullets">What we really like about all this being designed from the ground up to work together, every single element to work together, which is getting better results. And then the nurses and the techs that work in these rooms really appreciate the way the consoles and electronics were designed, they're very small, they're literally very light. They're very simple and easy to set up and use. The alarms, everything they have are very sensible. And they work very well with the catheter. And, we think that we're going to be able to make some hay with that.</p> <p class="paywall-full-content invisible no-summary-bullets">The other thing we love is just, when we have that controlled set of systems, all the different individual elements, we know where the noise is, we know how the connectors are supposed to be set up, we do it the same way every time when we set it up along with our mapping system. And we're just getting better and more consistent results and happier customers.</p> <p class="paywall-full-content invisible no-summary-bullets">So we're kind of pedal to the metal over there, in terms of that AcQBlate catheter and system launch as we speak. We're not really governing that back. We up to now have had some production capacity issues with the catheter, and I believe we are getting through that. We've invested significantly in our production capacity there from a catheter perspective.</p> <p class="paywall-full-content invisible no-summary-bullets">So, we're really pushing hard to really get a significant installed base. And we'd like to be one to one with our mapping systems, and also have some ablation stacks, even in centers where we don't have mapping systems as well, because it works very well on a standalone basis also.</p> <p class="paywall-full-content invisible no-summary-bullets">So, we're not really holding back in Europe, we're really pressing over there, and the team has just done a terrific job. And we're super eager to have all of that in the U.S. We've already -- we have, I think we have four or five stacks up and running in the U.S., supporting our IDE trial, which is just great for us, because our U.S. team now gets to experience the benefits of a system that was designed to work together, and they're having a lot of fun with that.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">David Roman</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">And Marie, maybe just to clarify. So from a modeling perspective, how this weaves into our guidance. A couple important things to point out here. First is, when we launched AcQBlate earlier this year, we did that through what we call limited market release, with the intention to understand how the product performs in a real world setting.</p> <p class="paywall-full-content invisible no-summary-bullets">During that time, we don't generate any revenue. We moved into full market release very late in the first quarter. There are some additional factors in the UK, where you have to get the NHS catalog listing to generate revenue. We applied for that in February, it's about a six month turnaround time. In the interim, we can sell AcQBlate on consignment in the UK, but have to defer that revenue. And we expect to recognize all that deferred revenue in Q3, which is another one of the factors that impacts the back-half loading of our year, but we would also expect production volumes to ramp materially throughout the year, as well.</p> <p class="paywall-full-content invisible no-summary-bullets">And as volumes ramp, we get this in the hands of our reps across all of Europe, as well as Biotronik, you should see an increased contribution quarter-by-quarter.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Marie Thibault</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Okay. Helpful insights from both. Thank you on that. Maybe I'll ask then on AcQCross. Tell us a little bit about how you're envisioning the launch here in the U.S., and then pushing forward in Europe as well with that product? Again, it's one I know that you've called out as a promising part of the whole portfolio. So, I'd love to hear how that adds to procedure ASPs over time here as well? And thanks for taking the questions tonight.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Vince Burgess</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Yeah, so the AcQCross launch in the U.S., if you've been following this, this is part of the acquisition we made a couple of years ago, a company called Rhythm Xience, we acquired that product line, we iterated it, we launched it into the market as a combination of the central crossing along with our own set of steerable and fixed per sheaths. And we saw really, really good feedback and uptake in both EP ablation and in structural heart.</p> <p class="paywall-full-content invisible no-summary-bullets">So we were seeing great utilization in LAA procedures and WATCHMAN procedures for that product line. One of the limitations that we saw in the EP space was by forcing a user to use not only our separate crossing device, also our sheath, we saw some friction from EP doctors around moving away from their sheath of choice. So what we did is we said, look, why do we want to fight that fight, let's meet them where they are, let's make this really novel effective, safe, fast, simple crossing device, compatible with the vast majority of the market leading sheaths that are used in ablation.</p> <p class="paywall-full-content invisible no-summary-bullets">And we identified that opportunity and executed on that very well. And we are now compatible with the Agilis from Abbott with the first cross from -- or the Vizigo from Biosense with SL1, and with the cryoballoon sheath from Medtronic, and of course with our own sheaths. Those catheters are linked to diameter matched, and transition matched and they lock into the hub at the back. So you can just go right in, cross the septum, hop out, and you've got your sheath of choice to guide your ablation without having to change your technique.</p> <p class="paywall-full-content invisible no-summary-bullets">Order magnitude from a procedural revenue perspective, I think we've talked publicly about our per procedural revenues for mapping base catheters of being a bit north of $5,000 a case. And I think, you can see a pretty clear path towards increasing that by about 10% in cases where they use our AcQCross products. So very nice opportunity there.</p> <p class="paywall-full-content invisible no-summary-bullets">I should point out about half of the accounts that are using these products, they don't even have our mapping systems yet. They're just using them on a standalone basis, because they love them and want to use them for their ablation cat procedures and their structural heart procedures. Those accounts where we don't have -- it's really fertile territory. It's a great brand builder for us, and door opener for us. </p> <p class="paywall-full-content invisible no-summary-bullets">We got a couple of accounts that I can think of right off the bat that once they get to know our rep, once they get to know our product and how we think about this market, all of a sudden they started asking about our mapping system. And it was a great door opener for us to get in there and start the contracting process to get a mapping system installed.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">David Roman</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">And one of those specific examples that Vince is referencing, actually I believe will be installed this week or next. So, we are seeing this as a nice door opener into new accounts.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Vince Burgess</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">So we expect to see the same in Europe, as relates both ablation and structural heart opportunities. There is a nuance in Europe that we're still trying to kind of wrap our heads around, which is the vast majority of cases they cross the septum under fluoro guidance, or using pressure differential as opposed to ice image guided septal crossing. And so we're going to go over there starting this month and work through the workflow issues.</p> <p class="paywall-full-content invisible no-summary-bullets">We're highly confident that it will be well-liked over there. We just have some workflow differences that we need to better understand, now that we have approval, and really make sure we work with those structural heart and EP partners to get this right coming out of the gate.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Marie Thibault</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Makes sense. Thank you.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Okay. There are no further questions at this time. This concludes today's conference call. Thank you for joining. You may now disconnect.</p></div><div class="above_now_read-piano-placeholder"></div><div><ul><li class="ja_E2" data-test-id="analysis-and-news-bullet">Read more current<!-- --> <!-- -->AFIB<!-- --> <a class="J_0 t_ej t_ek t_ep N_L N_gy" href="/symbol/AFIB"><span class="">analysis and news</span></a></li><li class="ja_E2" data-test-id="earnings-call-transcripts-bullet">View all<!-- --> <a class="J_0 t_ej t_ek t_ep N_L N_gy" href="/earnings/earnings-call-transcripts"><span class="">earnings call transcripts</span></a></li></ul></div></div></div></div><div class="piano-paywall-container"></div><div></div><footer class="nd_J t_ei t_es aP_i9 paywall-full-content" data-test-id="post-footer"><span class="ne_L ne_K5 t_ei t_ek s_am s_bq s_aw s_aU"><button class="uE_BS rI_Rx t_ei t_ek uE_jc" data-test-id="like-button" type="button"><svg viewBox="0 0 19 16" xmlns="http://www.w3.org/2000/svg" class="uE_fv"><path d="M17.8 7.18h-2.69V15h2.69zm-4.86 6.4s.1 1.32-1.34 1.32H4.26s-1.86-2.13-3.2-6.7C.64 6.78 2.7 6.57 2.7 6.57h5.17S5.9 4.04 5.7 2.21C5.5.38 7.26.69 8.39 2.71c1.14 2.04 4.55 3.86 4.55 3.86v7z"></path></svg><span class="uE_iM">Like</span></button></span><button aria-expanded="false" aria-label="Share options" class="flex shrink-0 items-center justify-center text-large-r text-black-35 dark:text-black-10" data-test-id="custom-share-button" type="button"><span class="truncate"><span class="ne_L ne_K5 t_ei t_ek s_am s_bq s_aw s_aU"><svg viewBox="0 0 18 18" xmlns="http://www.w3.org/2000/svg" class="ne_fv"><path d="M14.8 17.14a2.7 2.7 0 0 1-2.13-2.7l.01-.3-3.88-1.73-3.97-1.77c-.07-.03-.11 0-.3.17a2.67 2.67 0 1 1 0-3.83l.23.23 3.96-1.77 3.96-1.76-.01-.3c-.04-.7.24-1.44.74-1.97.64-.67 1.7-.96 2.6-.72A2.73 2.73 0 0 1 18 3.13a2.67 2.67 0 0 1-4.56 2.02l-.19-.18L9.3 6.73 5.33 8.5v.83l3.94 1.75 3.95 1.76.24-.22a2.67 2.67 0 1 1 1.35 4.52z"></path></svg><span class="ne_iM s_cs">Share</span></span></span></button><button aria-expanded="false" aria-label="Print options" class="flex shrink-0 items-center justify-center text-large-r text-black-35 dark:text-black-10" data-test-id="print-dropdown" type="button"><span class="truncate"><span class="ne_L ne_K5 t_ei t_ek s_am s_bq s_aw s_aU"><svg viewBox="0 0 14 13" xmlns="http://www.w3.org/2000/svg" class="ne_fv"><path d="M11.2 0H2.8v2.8h8.4V0zM0 3.5v6.3h2.8v2.8h8.4V9.8H14V3.5H0zm9.8 7.7H4.2V7.7h5.6v3.5zm2.48-4.93h-1.4v-1.4h1.4v1.4z"></path></svg><span class="ne_iM s_cs">Print</span></span></span></button><a class="ne_L ne_K5 t_ei t_ek s_am s_bq s_aw s_aU nd_K0" data-test-id="comment-button" href="/article/4428093-acutus-medical-inc-afib-ceo-vince-burgess-on-q1-2021-results-earnings-call-transcript#comments"><svg viewBox="0 0 16 15" xmlns="http://www.w3.org/2000/svg" class="ne_fv nd_K4"><path d="M7.04 12.28a8.8 8.8 0 0 1-4.6 2.21.79.79 0 0 1-.63-.2.91.91 0 0 1-.28-.45.61.61 0 0 1-.01-.4c0 .03-.01.04 0 .07-.03-.14.01-.21.1-.37l.08-.12.06-.07.05-.07.04-.04.23-.28.27-.32a4.07 4.07 0 0 0 .7-1.37 6.3 6.3 0 0 1-1.76-1.8 4.84 4.84 0 0 1-.17-5c.4-.73.94-1.36 1.62-1.88A7.87 7.87 0 0 1 5.12.95a9.23 9.23 0 0 1 6.6.32 6.87 6.87 0 0 1 2.74 2.12 4.93 4.93 0 0 1 0 6.05c-.68.9-1.6 1.6-2.74 2.12a8.97 8.97 0 0 1-4.68.72z" fill="none"></path></svg><span class="ne_iM s_cs">Comment</span></a></footer></div></div></div></section><!--$--><section class="mx-auto flex w-full flex-col justify-between bg-white dark:bg-black-95 pt-24 md:pt-12 pb-24 px-safe-offset-18 md:pb-20 md:px-safe-or-24 mb-8 md:mb-18 print:hidden" data-test-id="recommended-section"><div class="flex flex-col flex-wrap print:block"><div class="w-full max-w-full"><div class="paywall-full-content"><div class="w-full pb-6 pt-24 md:pb-10 md:pt-20"><div class="-mx-12 -my-4 flex flex-grow items-center flex-wrap"><div class="mr-auto flex flex-shrink flex-grow-0 px-12 py-4"><h4 class="m-0 inline-block text-5x-large-r text-black-35 dark:text-black-30 md:text-4x-large-r" data-test-id="recommended-for-you-card-title">Recommended For You</h4></div></div></div><div data-test-id="recommended-for-you-card-body"><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Avi Gilburt profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static1.seekingalpha.com/images/users_profile/000/876/837/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4643909-wells-fargo-is-developing-a-big-problem">Wells Fargo Is Developing A Big Problem</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Avi Gilburt</span></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Brad Thomas profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static1.seekingalpha.com/images/users_profile/000/330/973/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4644068-my-oh-my-2-strong-buys-residential-reits-that-help-me-sleep-well-at-night">My Oh My, 2 Strong Buys: Residential REITs That Help Me Sleep Well At Night</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Brad Thomas</span></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Tradevestor profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static.seekingalpha.com/images/users_profile/001/003/408/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4644414-altria-group-i-was-wrong-but-am-not-deterred">Altria Group: I Was Wrong But Am Not Deterred</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Tradevestor</span></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Michael A. Gayed, CFA profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static.seekingalpha.com/images/users_profile/000/039/580/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4642469-we-may-be-in-crash">We May Be In A Crash, And Here's Why</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Michael A. Gayed, CFA</span></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Rida Morwa profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static.seekingalpha.com/images/users_profile/000/016/392/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4643833-the-big-short-eisman-says-buy-bonds-and-old-economy-stocks">The 'Big Short' Eisman Says Buy Bonds And Old Economy Stocks</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Rida Morwa</span></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Mott Capital Management profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static3.seekingalpha.com/images/users_profile/026/750/043/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4643839-the-new-bull-market-is-over">The New Bull Market Is Over</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Mott Capital Management</span></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="lq_a t_ei t_ek t_ep" data-test-id="user-pic"><svg data-test-id="sprite-icon" class="lq_py lq_gi"><use xlink:href="#alpha"></use></svg></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4644249-wp-carey-will-still-yield-7-percent-after-dividend-cut">W. P. Carey Stock Will Still Yield 7% After The Dividend Cut (NYSE:WPC)</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Colorado Wealth Management Fund profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static.seekingalpha.com/images/users_profile/014/527/192/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4644122-disaster-strikes-mortgage-reits-under-siege">Disaster Strikes: Mortgage REITs Under Siege</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Colorado Wealth Management Fund</span></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Lawrence Fuller profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static1.seekingalpha.com/images/users_profile/007/375/661/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4637656-sell-everything">Sell Everything</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Lawrence Fuller</span></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Austin Craig profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static3.seekingalpha.com/images/users_profile/004/206/551/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4636632-lithium-americas-this-is-ridiculous">Lithium Americas: This Is Ridiculous</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Austin Craig</span></footer></div></div></div></article></div></div></div></div></section><div class="rJ_Ry" id="comments-card"><section class="mx-auto flex w-full flex-col justify-between bg-white dark:bg-black-95 pt-24 md:pt-12 pb-24 px-safe-offset-18 md:pb-20 md:px-safe-or-24 mb-8 md:mb-18 print:block" data-test-id="comments-section"><div class="flex flex-col flex-wrap print:block"><div class="w-full max-w-full"><div class="rJ_p1"><div class="paywall-full-content"><div class="ov_MV t_ei t_ek s_dX" data-scroll-id="comments" data-test-id="comments-header" id="comments"><h4 class="ov_Y t_ei t_ek aW_jr aW_jH aW_jQ s_cU s_dA" data-test-id="comments-counter">Comments</h4><div><button aria-expanded="false" aria-label="Sort By" class="flex shrink-0 items-center justify-center text-large-r text-black-35 dark:text-black-10" data-test-id="sort-comments-button" type="button"><span class="truncate"><span class="rE_Rr t_ei t_ek"><span class="rE_Rs s_c3 aY_lE aW_jm aW_jC aW_jQ">Newest</span><div class="sX_SS rE_fv t_ei t_ek"><span class="rE_Rt"><svg viewBox="0 0 15 16" xmlns="http://www.w3.org/2000/svg"><path d="M0 0h6.15v3.7H0V0zm0 6.15h11.08v3.7H0v-3.7zm0 6.16h14.77V16H0v-3.7z"></path></svg></span></div></span></span></button></div><button aria-expanded="false" aria-label="Comment options" class="flex shrink-0 items-center justify-center text-large-r text-black-35 dark:text-black-10 rG_Rw s_co" data-test-id="dropdown" type="button"><span class="truncate"><span class="rG_os t_ei t_ek t_ep"><svg class="rG_Rv"><use xlink:href="#info"></use></svg></span></span></button></div><!--$--><div class="uK_g qo_g s_dU aP_i9" data-test-id="add-comment-form"><div class="uK_Pt qo_Pt t_ei"><div class="uK_E3 s_c9"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><div class="" data-test-id="user-pic"></div></div></div><div class="uK_Pu qo_Pu"><div aria-label="Comment content" class="border border-black-10 bg-white text-black placeholder:text-black-35 read-only:text-black-35 read-only:bg-black-5 dark:border-black-80 dark:bg-black-98 dark:text-black-10 placeholder:text-black-35 read-only:text-black-35 dark:placeholder:text-black-30 dark:read-only:text-black-30 focus:border-black-35 dark:focus:border-black-30 rounded-tl-0 rounded-bl-8 rounded-r-8 uK_Pv qo_Pv s_dS s_ah s_aC s_a0 s_bl uv_Vl" contenteditable="true" data-test-id="add-comment-input" placeholder="Be the first to comment" role="textbox" tabindex="0"></div><div class="uK_yi qo_yi t_ei t_ek t_eq"><button disabled="" class="J_0 t_ej t_ek t_ep J_fP J_fz aW_jm aW_jC aW_jR uK_Px qo_Px s_cy" data-test-id="publish-comment-button" type="button"><span class="">Publish</span></button></div></div></div></div><div></div><div class="wI_iM s_bR aW_jm aW_jB aW_jQ"><span>To report an error in this transcript<!-- -->, <button class="J_0 t_ej t_ek t_ep yl_YH" data-test-id="report-problem-with-article" type="button"><span class="">click here</span></button>.</span>Contact us to<!-- --> <a data-test-id="transcript-add-your-company" href="/page/contact?question=Transcript%20Inquiries">add your company</a> <!-- -->to our coverage or<!-- --> <a data-test-id="transcript-in-your-business" href="/page/contact?question=Transcript%20Inquiries">use transcripts in your business</a>. Learn more about Seeking Alpha transcripts<!-- --> <a data-test-id="learn-more-about-transcripts" href="/page/sa_transcripts">here</a>.<!-- --> <!-- -->Your feedback matters to us!</div><!--/$--></div></div></div></div></section></div><!--/$-->